Bill Haney, Skyhawk

Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

Roche’s Genen­tech has just com­plet­ed the lat­est in a string of dis­cov­ery deals with a line­up of much, much small­er com­pa­nies look­ing to do new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA